Feldan Therapeutics Appoints David J. Mazzo, Ph.D. and Iain D. Dukes, Ph.D. to Board of Directors

Feldan Therapeutics, a biotechnology company that develops therapeutics based on the intracellular delivery of proteins and peptides, announces the appointment of Dr. David J. Mazzo and Dr. Iain D. Dukes as independent members of its board of directors.

“We are pleased to welcome Drs. Mazzo and Dukes to our board. They are two highly accomplished biopharmaceutical executives who bring many years of operational, strategic and financing expertise to Feldan,” said François-Thomas Michaud, co-founder and chief executive officer of Feldan. “The addition of these two directors complements our board of directors’ skills and experience, and will provide valuable guidance and vision as Feldan moves toward its first CTA/IND filing and next round of financing.”